Remote Health Systems Director — Strategic Accounts

CG Oncology, Inc.; Northern (KY); Hybrid; USD 225,000 - 240,000; Full time

Benefits offered by this job

Equity

401K match

Unlimited PTO

Well-Being Benefits

Job summary

CG Oncology, Inc. is seeking a Health Systems Director (Southwest) to lead strategic account plans, align with field leadership, and drive demand across national and regional health systems, academic centers, and IDNs.

This remote, US-based role requires strong senior relationships, travel up to 75%, and a track record in oncology or uro-oncology sales, with a focus on making CG’s launches successful.

Qualifications

• Bachelor’s degree required; MBA or other advanced degree preferred.
• Five (5) years of proven commercial experience in biopharmaceuticals or medical devices with 2–3 years in IDNs, Large Oncology or Urology practices, payers, and national/regional hospital systems.
• Minimum 2 years in Uro-Oncology/Urology/Oncology/Precision Medicine or specialty sales.
• Travel as required, up to 75%.
• Deep knowledge of hospital ecosystems, large group practices, and buy-and-bill processes.

Responsibilities

• Develop and execute strategic account plans for Health Systems, Private Equity/Top LUGPAs/IDNs/Academic groups.
• Drive demand and pull-through across National & Regional markets.
• Lead engagement with senior stakeholders and cross-functional teams to meet CG’s launch goals.
• Align local market strategy with CG leadership and national initiatives.
• Foster long-term relationships with key accounts and stakeholders.

Skills

Strategic account planning

Healthcare sales

Relationship management

C-suite engagement

Market access

Education

Bachelor's degree

MBA or advanced degree

Job description

CG Oncology, Inc. is seeking a Health Systems Director (Southwest) to lead strategic account plans, align with field leadership, and drive demand across national and regional health systems, academic centers, and IDNs.

This remote, US-based role requires strong senior relationships, travel up to 75%, and a track record in oncology or uro-oncology sales, with a focus on making CG’s launches successful.